GSK acquires stake in Novartis’s consumer healthcare business
Date: 2018-03-28   Author: Dhananjay Punekar  Category: #market

GSK acquires stake in Novartis’s consumer healthcare business

GlaxoSmithKline, a renowned pharmaceutical giant, has announced that it will acquire 36.5% of the ownership rights in Novartis’s consumer healthcare venture for USD 13 billion in cash.  For the record, last week, GSK withdrew its acquisition bid for Pfizer’s consumer healthcare business through which it had expected to accrue nearly USD 20 billion in terms of revenue. Currently though, GSK is anticipated to take complete control of Novartis’s venture, including the Sensodyne toothpaste, Nicotinell patches, Panadol headache medicines, and muscle gel Voltaren.

Emma Walmsley, the CEO of GlaxoSmithKline has stated that the proposed deal will help in addressing the firm’s key capital allocation priorities and help GSK investors in realizing the complete value of the leading consumer healthcare firm. The move will increase adjusted earnings and cash flows resulting in the improved performance for the company, she says. Further on, Walmsley adds that the deal would help the organization invest its capital in other activities such as pharmaceuticals R&D.

As per reliable sources, this pact is expected to be finalized during the second quarter of this year subject to the necessary approvals. Vas Narasimhan, the CEO of Novartis, has said that the firm is likely to divest one of its many non-core assets at a rather lucrative price.

According to an official statement, Novartis will use the proceeds from the deal for expanding its business and for the bolt-on acquisitions. After the declaration, the firm has incidentally witnessed a 2.2% rise in the pre-market indications in Zurich.

GSK has announced that it will review Horlicks and other consumer nutrition products, which will also include an assessment of the share it holds in its Indian subsidiary - GSK Consumer Healthcare Limited. It has been speculated that numerous other pharma firms are likely to follow GSK’s footsteps, which would eventually support the expansion of the global consumer healthcare business.



About Author


Dhananjay Punekar

Dhananjay Punekar

Dhananjay currently works as a content writer at AlgosOnline. A post graduate in mathematics as well as business administration, he worked as a process executive in Infosys BPO Limited before switching his professional genre. Following his childhood passion, he opted fo...

Read More

More from Dhananjay


Post Recommendents

Titanium Sponge for Aerospace & Defense Market 2024: Opportunities, Demands and Growth Revenue
Author: Ronak Bora

U.S. is expected to witness sturdy growth of titanium sponge for aerospace & defense market over forecast period owing to large defense expenditure across the globe, and presence of the major aerospace players in the region. In addition, utili...


Automotive Cyber Security Market to Grow Exponentially Via Network Security Segment By 2024
Author: Ronak Bora

The network security dominates the automotive cyber security market and is projected to generate a market revenue of USD 236.4 million over the forecast timescale. The in-vehicle networks carry a variety of personal and operational identifiable in...


Automotive LiDAR Market 2024: Industry Growth, Top Key Players, Recent Trends & Forecast To 2024
Author: Ronak Bora

North America is dominating the automotive LiDAR market and accounts for over 70% of the total market. This growth can be attributed to the presence of a large number of automakers and tech giants. They have adopted various strategic initiatives t...